OBJECTIVE: Contrary to some clinical belief, there were quite a few studies regarding animal models of intracerebral hemorrhage (ICH) in vivo suggesting that prior use of statins may improve outcome after ICH. This study reports the effect of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor, simvastatin given before experimental ICH. METHODS: Fifty-one rats were subjected to collagenase-induced ICH, subdivided in 3 groups according to simvastatin treatment modality, and behavioral tests were done. Hematoma volume, brain water content and hemispheric atrophy were analyzed. Immunohistochemical staining for microglia (OX-42) and endothelial nitric oxide synthase (eNOS) was performed and caspase-3 activity was also measured. RESULTS: Pre-simvastatin therapy decreased inflammatory reaction and perihematomal cell death, but resulted in no significant reduction of brain edema and no eNOS expression in the perihematomal region. Finally, prior use of simvastatin showed less significant improvement of neurological outcome after experimental ICH when compared to post-simvastatin therapy. CONCLUSION: The present study suggests that statins therapy after ICH improves neurological outcome, but prior use of statins before ICH might provide only histological improvement, providing no significant impact on neurological outcome against ICH.
OBJECTIVE: Contrary to some clinical belief, there were quite a few studies regarding animal models of intracerebral hemorrhage (ICH) in vivo suggesting that prior use of statins may improve outcome after ICH. This study reports the effect of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor, simvastatin given before experimental ICH. METHODS: Fifty-one rats were subjected to collagenase-induced ICH, subdivided in 3 groups according to simvastatin treatment modality, and behavioral tests were done. Hematoma volume, brain water content and hemispheric atrophy were analyzed. Immunohistochemical staining for microglia (OX-42) and endothelial nitric oxide synthase (eNOS) was performed and caspase-3 activity was also measured. RESULTS: Pre-simvastatin therapy decreased inflammatory reaction and perihematomal cell death, but resulted in no significant reduction of brain edema and no eNOS expression in the perihematomal region. Finally, prior use of simvastatin showed less significant improvement of neurological outcome after experimental ICH when compared to post-simvastatin therapy. CONCLUSION: The present study suggests that statins therapy after ICH improves neurological outcome, but prior use of statins before ICH might provide only histological improvement, providing no significant impact on neurological outcome against ICH.
Authors: Matthew J McGirt; John R Lynch; Augusto Parra; Huaxin Sheng; Robert D Pearlstein; Daniel T Laskowitz; Dale A Pelligrino; David S Warner Journal: Stroke Date: 2002-12 Impact factor: 7.914
Authors: Neeraj S Naval; Tamer A Abdelhak; Paloma Zeballos; Nathalie Urrunaga; Marek A Mirski; Juan R Carhuapoma Journal: Neurocrit Care Date: 2008 Impact factor: 3.210
Authors: Walter Balduini; Erika Mazzoni; Silvia Carloni; Maria Grazia De Simoni; Carlo Perego; Luigi Sironi; Mauro Cimino Journal: Stroke Date: 2003-06-26 Impact factor: 7.914
Authors: M Gomis; A Ois; A Rodríguez-Campello; E Cuadrado-Godia; J Jiménez-Conde; I Subirana; A Dávalos; J Roquer Journal: Eur J Neurol Date: 2009-11-12 Impact factor: 6.089
Authors: H Tapia-Perez; M Sanchez-Aguilar; J G Torres-Corzo; I Rodriguez-Leyva; D Gonzalez-Aguirre; A Gordillo-Moscoso; C Chalita-Williams Journal: Cent Eur Neurosurg Date: 2009-02-05
Authors: Emilie FitzMaurice; Lauren Wendell; Ryan Snider; Kristin Schwab; Rishi Chanderraj; Cathrine Kinnecom; Kaveer Nandigam; Natalia S Rost; Anand Viswanathan; Jonathan Rosand; Steven M Greenberg; Eric E Smith Journal: Stroke Date: 2008-04-24 Impact factor: 7.914